Companies Weigh In On How To Tackle EU Regulatory & Reimbursement Barriers To Digital Therapeutics
Executive Summary
When it comes to digital therapeutics in Europe, EFPIA says there is a lack of harmonization in the regulatory requirements, and only Belgium and Germany offer value assessment, reimbursement and funding pathways, with more intermittent offerings in countries like France and UK.
You may also be interested in...
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
Additional Analyses Help Idorsia Secure English Funding For Chronic Insomnia Drug Quviviq
Quviviq is to become the first dual orexin receptor antagonist available on the National Health Service. Just over 20,000 people in England could receive treatment with the drug in its first year, says the health technology assessment institute, NICE.
Lack of Adequate Study Plan Prompts EMA Review Of Cardiovascular Risk With Mysimba
The European Medicines Agency is to recommend whether the marketing authorization for Currax’s weight management drug should be maintained, varied, suspended or revoked.